Haybury
60 followers
News
Syncona, Novartis back IL-2 immuno-oncology startup Anaveon
Syncona and Novartis have invested in Anaveon. | Syncona and Novartis have invested in Anaveon. The $35 million series A round sets Anaveon up to advance a preclinical asset designed to enhance anti-tumor immune responses. www.fiercebiotech.comBoehringer Ingelheim appoints new chief medical officer - PharmaTimes
Boehringer Ingelheim has announced the appointment of Dr Mehdi Shahid as chief medical officer.pharmatimes.comAbout us
Haybury are an Executive Search Consultancy who are committed to providing solutions and creating opportunities through innovation and collaboration. We focus solely within Life Sciences, working to place key people in key positions across leading pharmaceutical and biotech companies, CROs and start-ups. Our roles are...
Employees
Discover all 46 employees on XING.